Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors

Maguire, Rebecca; Drummond, Frances J.; Hanly, Paul; Gavin, Anna; Sharp, Linda

doi:10.1007/s00520-018-4633-z

Cited by 18 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, SDs are common as a post-treatment complication [ 59 ]. Finally, night shift work has been demonstrated to be positively associated with the PCa incidence [ 60 ].…”

Section: Modifiable (Preventable) Risk Factorsmentioning

confidence: 99%

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Kučera¹,

Pecen²,

Topolčan³

et al. 2020

EPMA Journal

View full text Add to dashboard Cite

In the early twenty-first century, societies around the world are facing the paradoxal epidemic development of PCa as a non-communicable disease. PCa is the most frequently diagnosed cancer for men in several countries such as the USA. Permanently improving diagnostics and treatments in the PCa management causes an impressive divergence between, on one hand, permanently increasing numbers of diagnosed PCa cases and, on the other hand, stable or even slightly decreasing mortality rates. Still, aspects listed below are waiting for innovate solutions in the context of predictive approaches, targeted prevention and personalisation of medical care (PPPM / 3PM). PCa belongs to the cancer types with the highest incidence worldwide. Corresponding economic burden is enormous. Moreover, the costs of treating PCa are currently increasing more quickly than those of any other cancer. Implementing individualised patient profiles and adapted treatment algorithms would make currently too heterogeneous landscape of PCa treatment costs more transparent providing clear “road map” for the cost saving. PCa is a systemic multi-factorial disease. Consequently, predictive diagnostics by liquid biopsy analysis is instrumental for the disease prediction, targeted prevention and curative treatments at early stages. The incidence of metastasising PCa is rapidly increasing particularly in younger populations. Exemplified by trends observed in the USA, prognosis is that the annual burden will increase by over 40% in 2025. To this end, one of the evident deficits is the reactive character of medical services currently provided to populations. Innovative screening programmes might be useful to identify persons in suboptimal health conditions before the clinical onset of metastasising PCa. Strong predisposition to systemic hypoxic conditions and ischemic lesions (e.g. characteristic for individuals with Flammer syndrome phenotype) and low-grade inflammation might be indicative for specific phenotyping and genotyping in metastasising PCa screening and disease management. Predictive liquid biopsy tests for CTC enumeration and their molecular characterisation are considered to be useful for secondary prevention of metastatic disease in PCa patients. Particular rapidly increasing PCa incidence rates are characteristic for adolescents and young adults aged 15–40 years. Patients with early onset prostate cancer pose unique challenges; multi-factorial risks for these trends are proposed. Consequently, multi-level diagnostics including phenotyping and multi-omics are considered to be the most appropriate tool for the risk assessment, prediction and prognosis. Accumulating evidence suggests that early onset prostate cancer is a distinct phenotype from both aetiological and clinical perspectives deserving particular attention from view point of 3P medical approaches.

show abstract

“…Further, SDs are common as a post-treatment complication [ 59 ]. Finally, night shift work has been demonstrated to be positively associated with the PCa incidence [ 60 ].…”

Section: Modifiable (Preventable) Risk Factorsmentioning

confidence: 99%

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Kučera¹,

Pecen²,

Topolčan³

et al. 2020

EPMA Journal

View full text Add to dashboard Cite

show abstract

“…It is possible that men experience discomfort due to diarrhoea or constipation and, as for urinary incontinence, may worry about leakage and embarrassment from wearing bowel incontinence pads. As well as the adverse psychological and physical effects, these physical symptoms may cause sleep disturbance [41]; sleep disorders, in turn, are linked with cancer-related fatigue [42]. Thus, the constellation of consequences of these post-treatment symptoms may explain their association with the pain-fatiguedepression symptom cluster.…”

Section: Factors Associated With the Symptom Clustermentioning

confidence: 99%

Pain, fatigue and depression symptom cluster in survivors of prostate cancer

Baden

Drummond

et al. 2020

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Purpose Pain, fatigue and depression are common sequelae of a cancer diagnosis. The extent to which these occur together in prostate cancer survivors is unknown. We (i) investigated prevalence of the pain-fatigue-depression symptom cluster and (ii) identified factors associated with experiencing the symptom cluster among prostate cancer survivors. Methods Men in Ireland diagnosed with prostate cancer 2-18 years previously were identified from population-based cancer registries and sent postal questionnaires. Cancer-related pain and fatigue were measured using the EORTC QLQ-C30 and depression using the DASS-21. Cut-offs to define 'caseness' were pain ≥ 25, fatigue ≥ 39 and depression ≥ 10. Associations between survivor-related factors, clinical variables and specific prostate cancer physical symptoms and the symptom cluster were assessed using multivariate logistic regression. Results A total of 3348 men participated (response rate = 54%). Twenty-four percent had clinically significant pain, 19.7% had clinically significant fatigue, and 14.4% had depression; 7.3% had all three symptoms. In multivariate analysis, factors significantly associated with the symptom cluster were living in Northern Ireland, experiencing back pain at diagnosis and being affected by incontinence, loss of sexual desire, bowel problems, gynecomastia and hot flashes post-treatment. There was a strong association between the cluster and health-related quality of life. Conclusions The pain-fatigue-depression symptom cluster is present in 1 in 13 prostate cancer survivors. Physical after-effects of prostate cancer treatment are associated with this cluster. More attention should be paid to identifying and supporting survivors who experience multiple symptoms; this may help health-related quality of life improve among the growing population of prostate cancer survivors.

show abstract

“…Therefore, there is an urgent need for healthcare personnel to provide related diagnosis and treatment, as well as prognostic management and services to reduce sleep disorders in cancer survivors. 24 The average sleep time of the patients in this study was approximately 6.87 h after treatment. Although most of the patients also claimed to have good sleep quality, a detailed analysis of the data showed that 34.8% of the patients did not fall asleep within 30 min, more than three times in the month before treatment, while only 17.4% remained affected after treatment, representing a 50% improvement.…”

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Improved urinary melatonin level as the perspective indicator that leads to better sleeping quality in bladder cancer patients

Cheng

Lee

Chang

et al. 2020

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Individuals with higher-than-average melatonin concentrations are less likely to develop cancer. In cancer patients, psychosomatic coping patterns and treatment side effects are important indicators of cancer prevention and immune system deterioration. This study focused on changes in the urinary melatonin concentration, life resilience, and sleep quality in bladder cancer patients before, and 3 months after, treatment. Methods: A controlled before-and-after study was performed. The subjects were patients who were previously diagnosed with bladder cancer and had received treatment (transurethral resection of bladder tumor + intravesical chemotherapy). Data from 23 subjects were analyzed. Results: The results showed a significant difference in the melatonin concentration before and after treatment (Wilcoxon signed-rank test, Z = −2.220, p = 0.026). The melatonin concentration in 16 patients (70%) increased after treatment. The mean Pittsburgh Sleep Quality Index (PSQI) score before treatment was 7.348 (SD = 4.030), which was associated with poor sleep quality. The mean PSQI score after treatment was 6.435 (SD = 3.300; Z = −2.071; p = 0.038). These results represent the improved sleep quality in patients post-treatment. Conclusions: After treatment, the urinary melatonin concentration and sleep quality (PSQI) improved, both of which were statistically significant in bladder cancer patients. Consequently, bladder cancer treatment should be initiated as soon as possible. There was no significant difference in overall life resilience before and after treatment, possibly because elderly individuals have strong personality traits and emotional stability and are not easily affected by life events or stress.

show abstract

Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors

Abstract: Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors. Supportive Care in Cancer.

Cited by 18 publications

References 43 publications

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions

Pain, fatigue and depression symptom cluster in survivors of prostate cancer

Improved urinary melatonin level as the perspective indicator that leads to better sleeping quality in bladder cancer patients

Contact Info

Product

Resources

About